HGH Fragment 176-191 (HGH Frag)
Growth Hormone Fragment | Fat Loss Peptide
Community Research
Join others researching HGH Fragment 176-191 — share findings, ask questions, and learn from real experiences
HGH Fragment 176-191 is the fat-burning segment of human growth hormone, corresponding to amino acids 176 through 191 of the full GH molecule. It stimulates lipolysis and inhibits lipogenesis without the growth-promoting or insulin-disrupting effects associated with full-length HGH. AOD-9604 is a modified version of this fragment with an added N-terminal tyrosine residue.
Mimics the lipolytic region of human growth hormone by stimulating fat breakdown through beta-3 adrenergic receptor pathways. Unlike full HGH, it does not bind the growth hormone receptor, so it does not increase IGF-1 levels or interfere with glucose metabolism. The fragment selectively targets adipose tissue to promote fat oxidation.
Molecular Data
Leucine
Position 1
Arginine
Position 2
Isoleucine
Position 3
Valine
Position 4
Glutamine
Position 5
Cysteine
Position 6
Position 7
Serine
Position 8
Position 9
Glutamic Acid
Position 10
Glycine
Position 11
Position 12
Position 13
Position 14
Phenylalanine
Position 15
Research Indications
Increases fat oxidation and breakdown of stored triglycerides in adipose tissue without affecting glucose homeostasis.
Reduces new fat synthesis and storage, complementing the lipolytic action for overall fat reduction.
Promotes selective fat loss while preserving lean mass, particularly effective when combined with a caloric deficit and exercise.
Dosing Protocols
Subcutaneous injection is the standard route. Best administered twice daily on an empty stomach -- once in the morning and once before bed. Avoid eating for at least 30 minutes after injection for optimal fat-burning effect.
Fat loss - Standard
250mcg
Twice daily (morning fasted + pre-bed)
SubQ
Enhanced fat loss
500mcg
Conservative start
Once daily (morning, fasted)
Reconstitution Instructions
Lyophilized HGH Frag 176-191 vial
Bacteriostatic water (BAC water)
Insulin syringes (0.5-1mL)
Alcohol swabs
Sterile work surface
1 Allow vial to reach room temperature (15-20 minutes)
2 Calculate required bacteriostatic water volume
3 Clean vial stopper with alcohol swab
4 Draw BAC water into syringe
5 Inject slowly down vial side (not directly onto powder)
6 Gently swirl until dissolved (never shake vigorously)
7 Store reconstituted solution at 2-8 degrees C
8 Use within 28 days
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
Injection site irritation (redness, mild swelling)
Headache, particularly in the first few days
Generally well-tolerated with a favorable safety profile
Stop Signs - Discontinue if:
Severe injection site reactions or signs of infection
Hypoglycemia symptoms if combined with insulin (dizziness, sweating, confusion)
Allergic reactions (rare)
Any persistent or concerning symptoms
Contraindications
Pregnancy or breastfeeding
Active cancer or history of malignancy
WADA prohibited - athletes subject to testing must avoid
Quality Checklist
Good Signs
White lyophilized powder with uniform appearance
Crystal clear solution without particles after reconstitution
Certificate of Analysis showing >98% purity by HPLC
Proper cold-chain shipping
Warning Signs
Not FDA approved - research chemical only
WADA prohibited substance
Bad Signs
Discolored or clumped powder (yellow indicates degradation)
Cloudy solution after reconstitution
Collapsed or moisture-damaged appearance
Frequently Asked Questions
Is HGH Fragment 176-191 safe to use with insulin?
HGH Frag 176-191 does not affect blood glucose or insulin sensitivity directly, unlike full-length HGH. However, you should still monitor blood glucose if combining with insulin due to the fragment's lipolytic effects and the potential for unpredictable metabolic changes.
Can I combine HGH Fragment 176-191 with full-length HGH?
Not recommended. HGH already contains the 176-191 sequence, so adding the fragment provides redundant lipolytic action while increasing HGH-related side effects without proportional fat-loss benefit. Choose one or the other.
How quickly will I see fat loss from HGH Fragment 176-191?
Fat loss typically becomes noticeable around week 3-4 with proper diet and exercise. Weeks 5-8 show more significant reduction. Most users run 8-12 week cycles, with continued benefits observable through week 12.
Do I need to fast before injecting HGH Fragment 176-191?
Yes. Fasting is important for optimal effect. Inject on an empty stomach and wait at least 30 minutes before eating. Elevated insulin from food intake can suppress the lipolytic signaling that makes this fragment effective.
References
Both hGH and the C-terminal fragment (176-191) reduced body weight gain, increased fat oxidation, and stimulated lipolysis in obese ob/ob mice without affecting glucose metabolism.
The hGH fragment and its modified form AOD-9604 both increased beta-3 adrenergic receptor expression in obese mice. Effects were abolished in beta-3-AR knockout mice, confirming this receptor pathway is essential for the lipolytic action.
Characterized the metabolic properties of the hGH 176-191 lipolytic domain, demonstrating antilipogenic activity independent of the growth hormone receptor.
Oral treatment with the synthetic hGH fragment for 30 days significantly reduced body weight gain and altered lipogenic and lipolytic activity in adipose tissue of obese mice.
Related Peptides
Both target fat loss through complementary adrenergic pathways. The combination may enhance lipolysis beyond either compound alone.
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.